NASDAQ · DRUG
Bright Minds Biosciences financials
$49.74−3.72%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$9.2M | -$2.1M | -$5.4M | -$10.8M |
| Net income | -$8.1M | -$2.1M | -$5.4M | -$10.8M |
| Net margin | — | — | — | — |
| Diluted EPS | $-1.18 | $-0.48 | $-1.46 | $-4.38 |
| EBITDA | -$9.2M | -$2.0M | -$5.4M | -$10.8M |
| Operating cash flow | -$5.7M | -$1.4M | -$5.2M | -$9.8M |
| Free cash flow | -$5.7M | -$1.4M | -$5.2M | -$9.8M |
| Diluted shares | 6.9M | 4.3M | 3.7M | 2.5M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $54.8M | $4.2M | $5.0M | $8.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $55.8M | $4.5M | $5.1M | $8.7M |
| Total liabilities | $1.6M | $420.1K | $206.7K | $1.1M |
| Shareholders' equity | $54.2M | $4.1M | $4.9M | $7.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology